parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in urothelial cells	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	14 Parkinson's papers of 193	0.64
pathways Reactome	1 pathway; mostly lysosome and autophagy	1.00

No case: the score is under the bar. Receipt 5490

receipt 5500: FA2H in dopamine neurons, braak

power: full sample -0.36 (p 0.140, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.31 (p 0.204, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.164, n 18). could be the mix.
skeptic: leave-one-out range -0.53 to -0.27, sign flips 0; without severely affected donors -0.36 (p 0.140, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FA2H in dopamine neurons.

case closed: nothing better to follow up.

receipt 5499: FA2H in oligodendrocytes, braak

power: full sample +0.01 (p 0.962, n 18), 95% CI -0.46 to +0.48. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.990, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.03 (p 0.894, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.10, sign flips 7; without severely affected donors +0.01 (p 0.962, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FA2H in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts